Progress of 5-HT2A receptor antagonists in treatment of hallucinatory symptoms induced by neuropsychiatric disorders
10.3867/j.issn.1000-3002.2024.05.008
- VernacularTitle:5-HT2A受体拮抗剂治疗神经精神疾病幻觉症状研究进展
- Author:
Yu ZHAO
1
,
2
;
Aibing CHEN
;
Gang YU
;
Ruibin SU
Author Information
1. 河北科技大学化学与制药工程学院,河北 石家庄 050018
2. 军事科学院军事医学研究院国家安全特需药品全国重点实验室,神经精神药理学北京市重点实验室,北京 100850
- Keywords:
5-HT2A receptor;
psychotropic drugs;
antagonist;
hallucination
- From:
Chinese Journal of Pharmacology and Toxicology
2024;38(5):384-391
- CountryChina
- Language:Chinese
-
Abstract:
Neuropsychiatric disorders such as Parkinson disease,Alzheimer disease,and schizo-phrenia may induce hallucinations,delusions,and other psychiatric symptoms during the course of disease development.These symptoms are highly prevalent and difficult to cure,and have a impact on the lives of patients.Classical antipsychotic drugs such as chlorpromazine,sulpiride and perphenazine can con-trol related symptoms,but they can also cause uncontrollable extrapyramidal system reactions and side effects such as hyperprolactinemia.In recent years,it has been found that non-classical antipsy-chotics such as olanzapine,clozapine,risperidone and pimovanserin can treat hallucinatory symptoms in neuropsychiatric disorders by antagonising the 5-hydroxytryptamine 2A(5-HT2A)receptor,or by antago-nising both the 5-HT2A receptor(strong)and the dopamine 2(D2)receptor(weak).In preclinical studies,non-classical antipsychotic drugs have shown great therapeutic effects against hallucination induced by multiple factors.Clinical studies have confirmed that these drugs improve psychotic symptoms(mainly hallucinations and delusions)significantly.In patients who are insensitive or tolerant to clozapine and risperidone,pimavanserin still shows therapeutic effects.At the same time,the incidence and severity of adverse reactions to non-classical antipsychotic drugs are reduced,and they are well tolerated.This article reviews the research progress in the role of 5-HT2A receptor antagonists in attenuating hallucino-genic symptoms so as to provide reference for the design and development of new therapeutic drugs.
